{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:32:52Z","timestamp":1790040772237,"version":"4.0.1"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>\n                    CKD is common in patients with heart failure, associated with high mortality and morbidity, which is even higher in people undergoing long-term dialysis. Despite increasing use of evidence-based drug and device therapy in patients with heart failure in the general population, patients with CKD have not benefitted. This review discusses prevalence and evidence of kidney replacement, device, and drug therapies for heart failure in CKD. Evidence for treatment with\n                    <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                    -blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, and sodium-glucose cotransporter inhibitors in mild-to-moderate CKD has emerged from general population studies in patients with heart failure with reduced ejection fraction (HFrEF).\n                    <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                    -Blockers have been shown to improve outcomes in patients with HFrEF in all stages of CKD, including patients on dialysis. However, studies of HFrEF selected patients with creatinine &lt;2.5 mg\/dl for ACE inhibitors, &lt;3.0 mg\/dl for angiotensin-receptor blockers, and &lt;2.5 mg\/dl for mineralocorticoid receptor antagonists, excluding patients with severe CKD. Angiotensin receptor neprilysin inhibitor therapy was successfully used in randomized trials in patients with eGFR as low as 20 ml\/min per 1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    . Hence, the benefits of renin-angiotensin-aldosterone axis inhibitor therapy in patients with mild-to-moderate CKD have been demonstrated, yet such therapy is not used in all suitable patients because of fear of hyperkalemia and worsening kidney function. Sodium-glucose cotransporter inhibitor therapy improved mortality and hospitalization in patients with HFrEF and CKD stages 3 and 4 (eGFR&gt;20 ml\/min per 1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    ). High-dose and combination diuretic therapy, often necessary, may be complicated with worsening kidney function and electrolyte imbalances, but has been used successfully in patients with CKD stages 3 and 4. Intravenous iron improved symptoms in patients with heart failure and CKD stage 3; and high-dose iron reduced heart failure hospitalizations by 44% in patients on dialysis. Cardiac resynchronization therapy reduced death and hospitalizations in patients with heart failure and CKD stage 3. Peritoneal dialysis in patients with symptomatic fluid overload improved symptoms and prevented hospital admissions. Evidence suggests that combined cardiology-nephrology clinics may help improve management of patients with HFrEF and CKD. A multidisciplinary approach may be necessary for implementation of evidence-based therapy.\n                  <\/jats:p>","DOI":"10.2215\/cjn.14180920","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T12:18:14Z","timestamp":1611577094000},"page":"1131-1139","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":106,"title":["Management of Heart Failure Patient with CKD"],"prefix":"10.2215","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04435626","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6863-2325","authenticated-orcid":false,"given":"Debasish","family":"Banerjee","sequence":"first","affiliation":[{"name":"Renal and Transplantation Unit, St George\u2019s University Hospitals National Health Service Foundation Trust, London, United Kingdom"},{"name":"Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St Georges, University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[{"name":"Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St Georges, University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Herzog","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Internal Medicine, Hennepin Healthcare\/University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1681\/ASN.2006101159","article-title":"Reduced kidney function as a risk factor for incident heart failure: The Atherosclerosis Risk in Communities (ARIC) study","volume":"18","author":"Kottgen","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/eurheartj\/ehv010","article-title":"The kidney in heart failure: An update","volume":"36","author":"Damman","year":"2015","journal-title":"Eur Heart J"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/eurheartj\/ehn102","article-title":"Prevalence and significance of unrecognized renal insufficiency in patients with heart failure","volume":"29","author":"Amsalem","year":"2008","journal-title":"Eur Heart J"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ehf2.12185","article-title":"Impaired renal function affects clinical outcomes and management of patients with heart failure","volume":"4","author":"Jenkins","year":"2017","journal-title":"ESC Heart Fail"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/CIRCHEARTFAILURE.111.963256","article-title":"Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction","volume":"4","author":"Testani","year":"2011","journal-title":"Circ Heart Fail"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ahj.2014.08.016","article-title":"Transient and persistent worsening renal function during hospitalization for acute heart failure","volume":"168","author":"Krishnamoorthy","year":"2014","journal-title":"Am Heart J"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2016.06.423","article-title":"Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies: Insights from the DOSE trial","volume":"22","author":"Brisco","year":"2016","journal-title":"J Card Fail"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.kint.2019.05.019","article-title":"Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction","volume":"96","author":"McCallum","year":"2019","journal-title":"Kidney Int"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcin.2013.06.016","article-title":"Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: Insights from the NCDR Cath-PCI registry","volume":"7","author":"Tsai","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/eurjhf\/hft060","article-title":"Venous congestion and renal function in heart failure ... it\u2019s complicated","volume":"15","author":"Testani","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/00015385.2018.1455947","article-title":"Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome","volume":"74","author":"Verbrugge","year":"2019","journal-title":"Acta Cardiol"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1161\/CIRCULATIONAHA.117.030112","article-title":"Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury","volume":"137","author":"Ahmad","year":"2018","journal-title":"Circulation"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.ekir.2020.06.031","article-title":"Systematic review of the association between worsening renal function and mortality in patients with acute decompensated heart failure","volume":"5","author":"Yamada","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","article-title":"Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: Insights from the SOLVD Treatment trial","volume":"167","author":"Bowling","year":"2013","journal-title":"Int J Cardiol"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.ajkd.2019.05.010","article-title":"Trends in kidney function outcomes following RAAS inhibition in patients with heart failure with reduced ejection fraction","volume":"75","author":"McCallum","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/heartjnl-2018-314158","article-title":"Change in renal function associated with drug treatment in heart failure: National guidance","volume":"105","author":"Clark","year":"2019","journal-title":"Heart"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive medications and the prevalence of hyperkalemia in a large health system","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ehf2.12265","article-title":"Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease","volume":"5","author":"Pitt","year":"2018","journal-title":"ESC Heart Fail"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B27-20241015","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"B28-20241015","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation"},{"key":"B29-20241015","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"B31-20241015","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"B32-20241015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"B33-20241015","first-page":"CD012466","article-title":"Pharmacological interventions for heart failure in people with chronic kidney disease","volume":"2","author":"Lunney","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B34-20241015","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"B35-20241015","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ejhf.59","article-title":"The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: An analysis from SHIFT","volume":"16","author":"Voors","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"B36-20241015","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B37-20241015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"B38-20241015","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"B39-20241015","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2215\/CJN.01110307","article-title":"Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload","volume":"2","author":"Banerjee","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"B40-20241015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurjhf\/hfs013","article-title":"Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure","volume":"14","author":"N\u00fa\u00f1ez","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"B41-20241015","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/eurjhf\/hfs035","article-title":"Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease","volume":"14","author":"Koch","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"B42-20241015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000380915","article-title":"Peritoneal dialysis in patients with refractory congestive heart failure: A systematic review","volume":"5","author":"Lu","year":"2015","journal-title":"Cardiorenal Med"},{"key":"B43-20241015","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fphys.2019.00310","article-title":"Peritoneal ultrafiltration in the long-term treatment of chronic heart failure refractory to pharmacological therapy","volume":"10","author":"Wojtaszek","year":"2019","journal-title":"Front Physiol"},{"key":"B44-20241015","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/eurheartj\/ehx045","article-title":"Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease","volume":"38","author":"Reddy","year":"2017","journal-title":"Eur Heart J"},{"key":"B45-20241015","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N Engl J Med"},{"key":"B46-20241015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/europace\/eut277","article-title":"Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies","volume":"16","author":"Makki","year":"2014","journal-title":"Europace"},{"key":"B47-20241015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.ajkd.2011.03.026","article-title":"Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States","volume":"58","author":"Charytan","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"B48-20241015","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1161\/CIRCULATIONAHA.119.039818","article-title":"Prophylactic use of implantable cardioverter-defibrillators in the prevention of sudden cardiac death in dialysis patients","volume":"139","author":"Jukema","year":"2019","journal-title":"Circulation"},{"key":"B49-20241015","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"L\u00f6fman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B50-20241015","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/ehf2.12796","article-title":"Management and outcomes of heart failure patients with CKD: Experience from an inter-disciplinary clinic","volume":"7","author":"Nguyen","year":"2020","journal-title":"ESC Heart Fail"},{"key":"B51-20241015","first-page":"80","article-title":"Cardio-nephrology MDT meetings play an important role in the management of cardiorenal syndrome","volume":"27","author":"Sankaranarayanan","year":"2020","journal-title":"Br J Cardiol"},{"key":"B52-20241015","doi-asserted-by":"crossref","first-page":"e14061","DOI":"10.1111\/ctr.14061","article-title":"Role of a cardio-renal multi-disciplinary team meeting in managing cardiovascular risk in patients on kidney transplant waitlists","volume":"34","author":"Junarta","year":"2020","journal-title":"Clin Transplant"},{"key":"B53-20241015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"B54-20241015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"B55-20241015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Yusuf","year":"1992","journal-title":"N Engl J Med"},{"key":"B56-20241015","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"B57-20241015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"B58-20241015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"B59-20241015","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"B60-20241015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.14180920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:25Z","timestamp":1786369405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.14180920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.14180920","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}